Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 2/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5333269 | 1.00 | ALDH1A1 (0.33) | ALDH1A1MAPTNPC1MEN1RAB9A | |
| SCHEMBL4516293 | 0.93 | ALDH1A1 (0.33) | ALDH1A1MAPTNPC1MEN1RAB9A | |
| SCHEMBL4520572 | 0.92 | ALDH1A1 (0.32) | ALDH1A1MAPTNPC1MEN1RAB9A | |
| SCHEMBL5332762 | 0.92 | ALDH1A1 (0.32) | ALDH1A1MAPTNPC1MEN1RAB9A | |
| SCHEMBL4513365 | 0.90 | NPC1 (0.34) | ALDH1A1MAPTNPC1MEN1RAB9A | |
| SCHEMBL13763493 | 0.87 | CTSL (0.35) | CTSL | |
| SCHEMBL4506610 | 0.86 | PPARG (0.34) | — | |
| SCHEMBL5334219 | 0.86 | PPARG (0.34) | — | |
| SCHEMBL4510272 | 0.84 | HTR1D (0.33) | ALDH1A1MAPTNPC1MEN1RAB9A | |
| SCHEMBL5316848 | 0.84 | HTR1D (0.33) | ALDH1A1MAPTNPC1MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | claimed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| WO-2007029062-A2 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | CYP3A4, CYP4B1, CYP3A5 | ALDH1A1 226/4885MAPT 1894/4885NPC1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.